Keywords: endo, gets, rights, orexo, rapinyl, firm, pharmaceuticals
Endo gets rights to Orexo's Rapinyl
Article | 23 August 2004
US firm Endo Pharmaceuticals says it has gained exclusive rights todevelop and market Sweden-based Orexo AB's patented sublingual muco-adhesive fentanyl ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
